Clinical

Dataset Information

0

CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.


ABSTRACT: Primary objectives: Response Rate (RR) per each line of therapy: assessed according to RECIST criteria 1.1 Primary endpoints: Response Rate (RR) per each line of therapy assessed according to RECIST criteria 1.1

DISEASE(S): Metastatic Colorectal Cancer,Pazienti Affetti Da Carcinoma Del Colonretto Metastatico Che Presentano Uno Stato Wild Type Di Ras E Braf Prima Dell’inizio Del Trattamento Di Prima Linea,Mcrc Patients With Ras/braf Wild Type Tumors At Start Of First Line Treatment

PROVIDER: 2540493 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-12-31 | GSE243572 | GEO
| 71671 | ecrin-mdr-crc
| 2191128 | ecrin-mdr-crc
| 2756173 | ecrin-mdr-crc
| 2746724 | ecrin-mdr-crc
| 2536396 | ecrin-mdr-crc
| 2537795 | ecrin-mdr-crc
| 2539311 | ecrin-mdr-crc
2016-12-15 | GSE91089 | GEO
| 2290258 | ecrin-mdr-crc